← Leaderboards
Margaret Von Mehren
Fox Chase Cancer Center
$5,005,730
Attributed
$6,881,724
Total exposure
7
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $868.9K · FY2009–25$1M$750K$500K$250K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,881,724 · 7
By mechanism
R01$3,220,031 · 2
P30$2,641,635 · 3
R21$1,020,058 · 2
Top collaborators
- Andrew K Godwin5 shared
- Lori Rink3 shared
- Annick D Van Den Abbeele2 shared
Most similar at Fox Chase Cancer Center
Same institution · by research overlap
- Andrew K Godwin$21,382,895
Others in their field
Top investigators on “Clinical Trials”
- Lawrence Corey · Fred Hutchinson Cancer Center$824,102,536
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$622,583,125
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$542,008,718
- Bambra Strokes · Ppd Development Lp$526,656,217
- Judith S. Currier · University Of California Los Angeles$504,273,077
Research focus
Clinical TrialsClinical ResearchProgramsMolecularMalignant NeoplasmsResearch SupportProtocols DocumentationComprehensive Cancer CenterResearch PersonnelFoxesMemberFundingBioinformaticsTreatment TrialRegulationTranslatingClinical DataInsightMinorityHealth SciencesEnsureBiologicalFox Chase Cancer CenterHealth System
Grant awards (30)
Clinical Protocol and Data Management$438,868
P30 · FY2025 · CA · contact PI
Elucidating the critical role of Wee1 in GIST$430,050
R01 · FY2025 · CA
Elucidating the critical role of Wee1 in GIST$408,548
R01 · FY2024 · CA
Elucidating the critical role of Wee1 in GIST$430,050
R01 · FY2023 · CA
Clinical Protocol and Data Management$61,359
P30 · FY2021 · CA · contact PI
Clinical Protocol and Data Management$259,757
P30 · FY2020 · CA · contact PI
Early Phase Clinical Research Support$196,126
P30 · FY2020 · CA · contact PI
Early Phase Clinical Research Support$8,695
P30 · FY2020 · CA · contact PI
Clinical Protocol and Data Management$8,695
P30 · FY2020 · CA · contact PI
Clinical Protocol and Data Management$243,028
P30 · FY2019 · CA · contact PI
Early Phase Clinical Research Support$183,495
P30 · FY2019 · CA · contact PI
Clinical Protocol and Data Management$233,100
P30 · FY2018 · CA · contact PI
Early Phase Clinical Research Support$175,368
P30 · FY2018 · CA · contact PI
Early Phase Clinical Research Support$10,869
P30 · FY2018 · CA · contact PI
Clinical Protocol and Data Management$10,869
P30 · FY2018 · CA · contact PI
Clinical Protocol and Data Management$5,967
P30 · FY2018 · CA · contact PI
Early Phase Clinical Research Support$5,967
P30 · FY2018 · CA · contact PI
Clinical Protocol and Data Management$233,091
P30 · FY2017 · CA · contact PI
Early Phase Clinical Research Support$175,361
P30 · FY2017 · CA · contact PI
Clinical Protocol and Data Management$223,143
P30 · FY2016 · CA · contact PI
Early Phase Clinical Research Support$167,877
P30 · FY2016 · CA · contact PI
The Molecular Actions of Imatinib Mesylate in GISTs$358,650
R01 · FY2013 · CA
Preliminary Evaluation of FDG-PET with anti-IGF-1R Targeted Therapy in GISTs$258,020
R21 · FY2013 · CA · contact PI
The Molecular Actions of Imatinib Mesylate in GISTs$365,276
R01 · FY2012 · CA
The Molecular Actions of Imatinib Mesylate in GISTs$370,916
R01 · FY2011 · CA
Preliminary Evaluation of FDG-PET with anti-IGF-1R Targeted Therapy in GISTs$273,938
R21 · FY2011 · CA · contact PI
The Molecular Actions of Imatinib Mesylate in GISTs$433,446
R01 · FY2010 · CA
The Molecular Actions of Imatinib Mesylate in GISTs$423,095
R01 · FY2009 · CA
Evaluation of the Vaccine rF-CEA(6D)/TRICOM +/-GM-CSF$241,800
R21 · FY2002 · CA
Evaluation of the Vaccine rF CEA(6D)/TRICOM GMCSF$246,300
R21 · FY2001 · CA